在市场营销后对deutetrabenazine的真实安全性分析:利用FDA不良事件报告系统 (FAERS) 数据库的不成比例性研究
相关实验视频
Updated: May 26, 2025
![An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F66708.jpg&w=3840&q=50)
10:33
An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use
Published on: May 24, 2024
648
Guangwei Qing1,2, Shiyi Ye1,2, Bo Wei3,4
1Department of Psychiatry, Jiangxi Mental Hospital & Affiliated Mental Hospital of Nanchang University, Nanchang, Jiangxi, 330029, China.
BMC pharmacology & toxicology
|February 22, 2025
概括
杜特特拉贝纳对神经系统疾病具有有效性,但存在风险. 现实世界的数据分析证实了已知的不良事件,并确定了新的安全信号,包括药物无效和跌倒,通常发生在治疗的第一个月内.
科学领域:
- 药物监督和药物安全研究.
- 神经学和运动障碍治疗学.
- 现实世界的证据生成.
背景情况:
- 杜特特拉贝纳是一种VMAT2抑制剂,用于治疗晚期运动障碍症和亨廷顿病.
- 潜在的不良事件 (AEs) 需要彻底的药物监测.
- 现实世界的安全评估对于临床使用至关重要.
研究的目的:
- 综合评估deutetrabenazine的现实安全概况.
- 分析来自FDA不良事件报告系统 (FAERS) 的不良事件报告.
- 识别潜在的安全信号和时间风险模式.
主要方法:
- 使用FAERS数据 (Q3 2017-Q3 2024) 的回顾性药监测研究.
- 应用了四种不成比例分析方法 (ROR,PRR,BCPNN,MGPS).
- 使用韦布尔分布模型进行时间风险分析.
主要成果:
- 从超过1050万份FAERS报告中分析了4337份与德特拉贝纳相关的AE报告.
- 确定了1,131个首选术语 (PT),表明了值得注意的不良反应.
- 确认了标签上列出的副作用 (抑郁症,昏昏欲睡) 和检测到的未标记的风险 (药物无效,跌倒,失眠,死亡).
- 大多数AE发生在第一个月内,平均发病时间为40.5天.
结论:
- 已验证的已知deutetrabenazine的不良反应.
- 发现了需要临床关注的潜在新安全风险.
- 这些发现为处方德特拉贝纳的医生提供了必要的安全考虑.
相关概念视频
Pharmacovigilance
764
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
764
Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Antiepileptic Drugs: Potassium Channel Activators
140
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
140
Hazard Ratio
77
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
77

